26 October 2016 - CADTH publishes final recommendation on prevention of cardiovascular mortality in type 2 diabetes mellitus.

The CADTH Canadian Drug Expert Committee has recommended that empagliflozin be reimbursed as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease who have inadequate glycemic control, if the following criteria are met:

• Patients have inadequate glycemic control despite an adequate trial of metformin hydrochloride
  
• Patients have established cardiovascular disease as defined in the EMPA-REG OUTCOME trial.
  

Read CADTH outcome for Jardiance